InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Zymeworks Inc.

ZYME Clue Score44
United States Fiscal year ends December CIK 0001937653 Results filed 6 Aug 2026
Add to watchlist

What the insiders did Scheduled selling only

Individual transactions

11
Insider
Date
Role
Action
Shares
Price
Amount
Adam Schayowitz
9 Oct 2026
EVP, Head of R&D
Sold after exercise
13,832
$25.85
$357.56K
Kenneth Galbraith
12 Jan 2026
Chair & CEO
Sold after exercise
30,424
$22.67
$689.82K
Paul Andrew Moore
12 Jan 2026
Chief Scientific Officer
Sold after exercise
9,560
$22.67
$216.76K
Jeffrey T L Smith
12 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
9,310
$22.67
$211.09K
Mark Hollywood
12 Jan 2026
EVP & Chief Operating Officer
Sold after exercise
6,120
$22.67
$138.76K
Paul Andrew Moore
5 Jan 2026
Chief Scientific Officer
Sold after exercise
10,821
$25.10
$271.57K
Paul Andrew Moore
5 Jan 2026
Chief Scientific Officer
Sold after exercise
9,289
$25.10
$233.13K
Kenneth Galbraith
5 Jan 2026
Chair & CEO
Sold after exercise
31,686
$25.10
$795.22K
Kenneth Galbraith
5 Jan 2026
Chair & CEO
Sold after exercise
22,657
$25.10
$568.62K
Jeffrey T L Smith
5 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
10,538
$25.10
$264.47K
Kenneth Galbraith
22 Dec 2025
Chair & CEO
Sold after exercise
47,528
$27.02
$1.28M

What was left out

Form 4 filings counted 22
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 11
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 426,935
History held since 17 Oct 2022